Arlevert is developed by Valenta Pharm JSC.

What development phase is Arlevert in?

Arlevert is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Arlevert

Valenta Pharm JSC · FDA-approved active Small molecule Quality 0/100

Arlevert, marketed by Valenta Pharm JSC, is a drug with a key composition patent expiring in 2028. The primary strength of Arlevert lies in its established market presence, supported by its current marketing status. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	Arlevert
Sponsor	Valenta Pharm JSC
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results